AtriCure (ATRC) 10-Q 3 Aug 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2022	Aug. 01, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	000-51470
Entity Registrant Name	AtriCure, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	34-1940305
Entity Address, Address Line One	7555 Innovation Way
Entity Address, City or Town	Mason
Entity Address, State or Province	OH
Entity Address, Postal Zip Code	45040
City Area Code	513
Local Phone Number	755-4100
Title of 12(b) Security	Common Stock, $.001 par value
Trading Symbol	ATRC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		46,424,652
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Central Index Key	0001323885

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 54,556	$ 43,654
Short-term investments	63,898	75,436
Accounts receivable, less allowance for credit losses of $1,096	41,488	33,021
Inventories	41,292	38,964
Prepaid and other current assets	4,932	5,001
Total current assets	206,166	196,076
Long-term investments	64,295	104,338
Property and equipment, net	36,053	31,409
Operating lease right-of-use assets	4,241	4,761
Intangible assets, net	41,049	42,992
Goodwill	234,781	234,781
Other noncurrent assets	804	955
Total Assets	587,389	615,312
Current liabilities:
Accounts payable	23,721	18,597
Accrued liabilities	30,775	36,092
Current maturities of leases	1,820	1,756
Total current liabilities	56,316	56,445
Long-term debt	59,954	59,741
Finance lease liabilities	9,603	10,082
Operating lease liabilities	3,591	4,068
Other noncurrent liabilities	1,215	1,220
Total Liabilities	130,679	131,556
Commitments and contingencies (Note 8)
Stockholders’ Equity:
Common stock, $0.001 par value, 90,000 shares authorized and 46,423 and 46,016 issued and outstanding	46	46
Additional paid-in capital	771,185	764,811
Accumulated other comprehensive loss	(4,344)	(948)
Accumulated deficit	(310,177)	(280,153)
Total Stockholders’ Equity	456,710	483,756
Total Liabilities and Stockholders’ Equity	$ 587,389	$ 615,312

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Accounts receivable, allowance for credit losses	$ 1,096
Common stock, par value (in usd per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	90,000,000	90,000,000
Common stock, shares issued (in shares)	46,423,000	46,016,000
Common stock, shares outstanding (in shares)	46,423,000	46,016,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Revenue	$ 84,529	$ 71,376	$ 159,105	$ 130,651
Cost of revenue	21,010	17,298	39,991	32,033
Gross profit	63,519	54,078	119,114	98,618
Operating expenses:
Research and development expenses	14,791	12,197	28,420	23,414
Selling, general and administrative expenses	62,388	56,958	118,504	106,166
Total operating expenses	77,179	69,155	146,924	129,580
Loss from operations	(13,660)	(15,077)	(27,810)	(30,962)
Other income (expense):
Interest expense	(1,101)	(1,197)	(2,101)	(2,386)
Interest income	76	103	192	237
Other	(111)	(14)	(204)	40
Loss before income tax expense	(14,796)	(16,185)	(29,923)	(33,071)
Income tax expense	45	66	101	97
Net loss	$ (14,841)	$ (16,251)	$ (30,024)	$ (33,168)
Net income (loss) per share
Basic net loss per share (in usd per share)	$ (0.32)	$ (0.36)	$ (0.66)	$ (0.74)
Diluted net loss per share (in usd per share)	$ (0.32)	$ (0.36)	$ (0.66)	$ (0.74)
Weighted average shares outstanding—basic and diluted
Weighted average shares outstanding—basic (in shares)	45,692	45,035	45,610	44,834
Weighted average shares outstanding—diluted (in shares)	45,692	45,035	45,610	44,834
Comprehensive loss:
Unrealized loss on investments	$ (449)	$ (132)	$ (2,788)	$ (163)
Foreign currency translation adjustment	(430)	63	(608)	(236)
Other comprehensive loss	(879)	(69)	(3,396)	(399)
Net loss	(14,841)	(16,251)	(30,024)	(33,168)
Comprehensive loss, net of tax	$ (15,720)	$ (16,320)	$ (33,420)	$ (33,567)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)
Beginning Balance (in shares) at Dec. 31, 2020		45,346
Beginning Balance at Dec. 31, 2020	$ 412,394	$ 45	$ 742,389	$ (330,352)	$ 312
Impact of equity compensation plans (in shares)		535
Impact of equity compensation plans	6,256	$ 1	6,255
Other comprehensive loss	(399)				(399)
Net loss	(33,168)			(33,168)
Ending Balance (in shares) at Jun. 30, 2021		45,881
Ending Balance at Jun. 30, 2021	385,083	$ 46	748,644	(363,520)	(87)
Beginning Balance (in shares) at Mar. 31, 2021		45,623
Beginning Balance at Mar. 31, 2021	391,243	$ 46	738,484	(347,269)	(18)
Impact of equity compensation plans (in shares)		258
Impact of equity compensation plans	10,160		10,160
Other comprehensive loss	(69)				(69)
Net loss	(16,251)			(16,251)
Ending Balance (in shares) at Jun. 30, 2021		45,881
Ending Balance at Jun. 30, 2021	385,083	$ 46	748,644	(363,520)	(87)
Beginning Balance (in shares) at Dec. 31, 2021		46,016
Beginning Balance at Dec. 31, 2021	483,756	$ 46	764,811	(280,153)	(948)
Impact of equity compensation plans (in shares)		407
Impact of equity compensation plans	6,374		6,374
Other comprehensive loss	(3,396)				(3,396)
Net loss	(30,024)			(30,024)
Ending Balance (in shares) at Jun. 30, 2022		46,423
Ending Balance at Jun. 30, 2022	456,710	$ 46	771,185	(310,177)	(4,344)
Beginning Balance (in shares) at Mar. 31, 2022		46,268
Beginning Balance at Mar. 31, 2022	462,825	$ 46	761,580	(295,336)	(3,465)
Impact of equity compensation plans (in shares)		155
Impact of equity compensation plans	9,605		9,605
Other comprehensive loss	(879)				(879)
Net loss	(14,841)			(14,841)
Ending Balance (in shares) at Jun. 30, 2022		46,423
Ending Balance at Jun. 30, 2022	$ 456,710	$ 46	$ 771,185	$ (310,177)	$ (4,344)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net loss	$ (30,024)	$ (33,168)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense	14,573	13,745
Depreciation	3,861	3,815
Amortization of intangible assets	1,943	965
Amortization of deferred financing costs	255	249
Loss on disposal of property and equipment	25	52
Amortization of investments	983	1,206
Change in fair value of contingent consideration	0	5,100
Other non-cash adjustments	654	472
Changes in operating assets and liabilities:
Accounts receivable	(8,757)	(10,799)
Inventories	(2,727)	(2,707)
Other current assets	32	(308)
Accounts payable	4,240	3,571
Accrued liabilities	(5,136)	4,529
Other noncurrent assets and liabilities	(325)	(571)
Net cash used in operating activities	(20,403)	(13,849)
Cash flows from investing activities:
Purchases of available-for-sale securities	(3,941)	(94,817)
Sales and maturities of available-for-sale securities	51,749	147,884
Purchases of property and equipment	(7,565)	(5,539)
Net cash provided by investing activities	40,243	47,528
Cash flows from financing activities:
Payments on leases	(437)	(399)
Proceeds from stock option exercises and employee stock purchase plan	3,374	9,010
Shares repurchased for payment of taxes on stock awards	(11,573)	(16,500)
Net cash used in financing activities	(8,636)	(7,889)
Effect of exchange rate changes on cash and cash equivalents	(302)	(115)
Net increase in cash and cash equivalents	10,902	25,675
Cash and cash equivalents—beginning of period	43,654	41,944
Cash and cash equivalents—end of period	54,556	67,619
Supplemental cash flow information:
Cash paid for interest	1,797	2,147
Cash paid for income taxes, net of refunds	132	128
Non-cash investing and financing activities:
Accrued purchases of property and equipment	$ 2,562	$ 529

Description of Business and Sum

Description of Business and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Summary of Significant Accounting Policies	DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of the Business —The “Company” or “AtriCure” consists of AtriCure, Inc. and its wholly-owned subsidiaries. The Company is a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, and sells its products to medical centers globally through its direct sales force and distributors. Basis of Presentation —The accompanying interim financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (SEC). All intercompany accounts and transactions have been eliminated in consolidation. The accompanying interim financial statements are unaudited, but in the opinion of the Company’s management, contain all normal, recurring adjustments considered necessary to present fairly the financial position, results of operations and cash flows for the periods presented in conformity with accounting principles generally accepted in the United States of America (GAAP) applicable to interim periods. Certain information and footnote disclosures included in annual financial statements prepared in accordance with GAAP have been omitted or condensed. The Company believes the disclosures herein are adequate to make the information presented not misleading. Results of operations are not necessarily indicative of the results expected for the full year or for any future period. The accompanying interim financial statements should be read in conjunction with the Company’s audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC. There have been no changes in the Company's significant accounting policies for the six months ended June 30, 2022 as compared to the significant accounting policies described in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC. Use of Estimates —The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including intangible assets, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Estimates are based on historical experience, where applicable, and other assumptions believed to be reasonable by management. Actual results could differ from those estimates. Segments —The chief operating decision maker for the Company is the Chief Executive Officer. The Chief Executive Officer reviews financial information presented on a consolidated basis, accompanied only by information about revenue by product type and geographic area, for purposes of allocating resources and evaluating financial performance. Accordingly, the Company has determined that it has a single operating segment. The Company’s long-lived assets are located primarily in the United States, except for $1,516 as of June 30, 2022 and $1,399 as of December 31, 2021 located primarily in Europe.

Fair Value

Fair Value	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value	FAIR VALUE The Financial Accounting Standards Board’s (FASB) Accounting Standards Codification (ASC) 820, “Fair Value Measurements and Disclosures” (ASC 820), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value: • Level 1—Quoted prices in active markets for identical assets or liabilities. • Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The following table represents the Company’s fair value hierarchy for its financial assets measured at fair value on a recurring basis as of June 30, 2022: Quoted Prices in Significant Other Significant Other Total Assets: Money market funds $ — $ 48,832 $ — $ 48,832 Commercial paper — 15,940 — 15,940 Government and agency obligations 31,735 — — 31,735 Corporate bonds — 66,789 — 66,789 Asset-backed securities — 13,729 — 13,729 Total assets $ 31,735 $ 145,290 $ — $ 177,025 There were no changes in the levels or methodology of measurement of financial assets and liabilities during the three and six months ended June 30, 2022. The following table represents the Company’s fair value hierarchy for its financial assets measured at fair value on a recurring basis as of December 31, 2021: Quoted Prices in Significant Other Significant Other Total Assets: Money market funds $ — $ 38,360 $ — $ 38,360 Commercial paper — 22,978 — 22,978 Government and agency obligations 32,690 — — 32,690 Corporate bonds — 95,845 — 95,845 Asset-backed securities — 28,261 — 28,261 Total assets $ 32,690 $ 185,444 $ — $ 218,134 Contingent Consideration.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2022
Inventory Disclosure [Abstract]
Inventories	INVENTORIES Inventories consist of the following: June 30, December 31, Raw materials $ 14,235 $ 12,653 Work in process 2,742 2,064 Finished goods 24,315 24,247 Total $ 41,292 $ 38,964

Intangible Assets

Intangible Assets	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	INTANGIBLE ASSETS The following table provides a summary of the Company’s intangible assets: June 30, 2022 December 31, 2021 Estimated Useful Life Cost Accumulated Cost Accumulated Technology 10 - 15 years $ 55,712 $ 14,663 $ 55,712 $ 12,720 Amortization expense of intangible assets was $971 and $727 for the three months ended June 30, 2022 and 2021 and $1,943 and $965 for the six months ended June 30, 2022 and 2021. Future amortization expense is projected as follows: 2022 (excluding the six months ended June 30, 2022) $ 1,710 2023 2,953 2024 2,953 2025 2,953 2026 2,953 2027 and thereafter 27,527 Total $ 41,049

Accrued Liabilities

Accrued Liabilities	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Accrued Liabilities	ACCRUED LIABILITIES Accrued liabilities consist of the following: June 30, December 31, Accrued compensation and employee-related expenses $ 25,197 $ 30,990 Sales returns and allowances 2,613 2,416 Accrued taxes and value-added taxes payable 1,572 1,452 Other accrued liabilities 1,393 1,234 Total $ 30,775 $ 36,092

Indebtedness

Indebtedness	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Indebtedness	INDEBTEDNESS Credit Facility. The Company has a Loan and Security Agreement, as amended and modified effective November 1, 2021 (Loan Agreement), with Silicon Valley Bank (SVB). The Loan Agreement includes a $60,000 term loan, a $30,000 revolving line of credit, and an option for an additional $30,000 in term loan borrowings. The Loan Agreement has a five year term, expiring November 2026. Principal payments under the Loan Agreement are to be made ratably commencing 24 months after inception through the loan's maturity date. At the option of the Company, the commencement of term loan principal payments may be extended an additional twelve months. The term loan accrues interest at the Prime Rate plus 1.25% and is subject to an additional 3.00% fee on the term loan principal amount at maturity. The Company is accruing the 3.00% fee over the term of the Loan Agreement, with $240 included in the outstanding loan balance as of June 30, 2022. Additionally, the unamortized original financing costs related to the term loan of $286 are netted against the outstanding loan balance in the Condensed Consolidated Balance Sheets and are amortized ratably over the term of the Loan Agreement. The revolving line of credit is subject to an annual facility fee of 0.20%, and any borrowings thereunder bear interest at the Prime Rate. Borrowing availability under the revolving credit facility is based on the lesser of $30,000 or a borrowing base calculation as defined by the Loan Agreement. As of June 30, 2022, the Company had no borrowings under the revolving credit facility and had borrowing availability of $28,750. The Loan Agreement also provides for certain prepayment and early termination fees, as well as establishes a minimum liquidity covenant and dividend restrictions, along with other customary terms and conditions. Specified assets have been pledged as collateral. Future maturities of long-term debt, excluding the term loan final fee, are projected as follows: 2022 (excluding the six months ended June 30, 2022) $ — 2023 3,333 2024 20,000 2025 20,000 2026 16,667 Total long-term debt $ 60,000

Leases

Leases	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Leases	LEASES The Company has operating and finance leases for office, manufacturing and warehouse facilities and equipment. The Company’s leases have remaining lease terms of less than one year to nine years. Options to renew or extend leases beyond their initial term have been excluded from measurement of the ROU assets and lease liabilities as exercise is not reasonably certain. The weighted average remaining lease term and the discount rate for the reporting periods are as follows: June 30, 2022 December 31, 2021 Operating Leases Weighted average remaining lease term (years) 4.8 3.6 Weighted average discount rate 4.66 % 4.69 % Finance Leases Weighted average remaining lease term (years) 8.1 8.6 Weighted average discount rate 6.92 % 6.91 % A $1,250 letter of credit issued to the lessor of the Company's corporate headquarters building is renewed annually and remains outstanding as of June 30, 2022. The components of lease expense are as follows: Three Months Ended Six Months Ended 2022 2021 2022 2021 Operating lease cost $ 284 $ 203 $ 570 $ 481 Finance lease cost: Amortization of right-of-use assets 338 242 508 484 Interest on lease liabilities 185 200 375 403 Total finance lease cost $ 523 $ 442 $ 883 $ 887 Short-term lease expense was not significant for the three and six months ended June 30, 2022 and 2021. Supplemental cash flow information related to leases was as follows: Six Months Ended Six Months Ended Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 505 $ 494 Operating cash flows for finance leases 375 403 Financing cash flows for finance leases 437 399 Right-of-use assets obtained in exchange for lease obligations: Operating leases — 1,221 Finance leases — — Supplemental balance sheet information related to leases was as follows: June 30, 2022 December 31, 2021 Operating Leases Operating lease right-of-use assets $ 4,241 $ 4,761 Current maturities of leases 884 861 Operating lease liabilities 3,591 4,068 Total operating lease liabilities $ 4,475 $ 4,929 Finance Leases Property and equipment, at cost $ 14,607 $ 14,607 Accumulated depreciation (6,624) (6,116) Property and equipment, net $ 7,983 $ 8,491 Current maturities of leases $ 936 $ 895 Finance lease liabilities 9,603 10,082 Total finance lease liabilities $ 10,539 $ 10,977 Future maturities of lease liabilities as of June 30, 2022 were as follows: Operating Leases Finance Leases 2022 (excluding the six months ended June 30, 2022) $ 356 $ 817 2023 1,160 1,652 2024 1,164 1,674 2025 920 1,625 2026 592 1,657 2027 and thereafter 868 6,515 Total payments $ 5,060 $ 13,940 Less imputed interest (585) (3,401) Total $ 4,475 $ 10,539
Leases	LEASES The Company has operating and finance leases for office, manufacturing and warehouse facilities and equipment. The Company’s leases have remaining lease terms of less than one year to nine years. Options to renew or extend leases beyond their initial term have been excluded from measurement of the ROU assets and lease liabilities as exercise is not reasonably certain. The weighted average remaining lease term and the discount rate for the reporting periods are as follows: June 30, 2022 December 31, 2021 Operating Leases Weighted average remaining lease term (years) 4.8 3.6 Weighted average discount rate 4.66 % 4.69 % Finance Leases Weighted average remaining lease term (years) 8.1 8.6 Weighted average discount rate 6.92 % 6.91 % A $1,250 letter of credit issued to the lessor of the Company's corporate headquarters building is renewed annually and remains outstanding as of June 30, 2022. The components of lease expense are as follows: Three Months Ended Six Months Ended 2022 2021 2022 2021 Operating lease cost $ 284 $ 203 $ 570 $ 481 Finance lease cost: Amortization of right-of-use assets 338 242 508 484 Interest on lease liabilities 185 200 375 403 Total finance lease cost $ 523 $ 442 $ 883 $ 887 Short-term lease expense was not significant for the three and six months ended June 30, 2022 and 2021. Supplemental cash flow information related to leases was as follows: Six Months Ended Six Months Ended Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 505 $ 494 Operating cash flows for finance leases 375 403 Financing cash flows for finance leases 437 399 Right-of-use assets obtained in exchange for lease obligations: Operating leases — 1,221 Finance leases — — Supplemental balance sheet information related to leases was as follows: June 30, 2022 December 31, 2021 Operating Leases Operating lease right-of-use assets $ 4,241 $ 4,761 Current maturities of leases 884 861 Operating lease liabilities 3,591 4,068 Total operating lease liabilities $ 4,475 $ 4,929 Finance Leases Property and equipment, at cost $ 14,607 $ 14,607 Accumulated depreciation (6,624) (6,116) Property and equipment, net $ 7,983 $ 8,491 Current maturities of leases $ 936 $ 895 Finance lease liabilities 9,603 10,082 Total finance lease liabilities $ 10,539 $ 10,977 Future maturities of lease liabilities as of June 30, 2022 were as follows: Operating Leases Finance Leases 2022 (excluding the six months ended June 30, 2022) $ 356 $ 817 2023 1,160 1,652 2024 1,164 1,674 2025 920 1,625 2026 592 1,657 2027 and thereafter 868 6,515 Total payments $ 5,060 $ 13,940 Less imputed interest (585) (3,401) Total $ 4,475 $ 10,539

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES Royalty Agreement. The Company has a royalty agreement in place with terms that include payment of royalties of 5% of specified product sales. The agreement terminates the later of 2023 or upon expiration of the underlying patents or patent applications, which is expected to occur after 2023. Parties to the royalty agreement have the right at any time to terminate the agreement immediately for cause. Royalty expense of $877 and $842 was recorded for the three months ended June 30, 2022 and 2021 and $1,670 and $1,564 for the six months ended June 30, 2022 and 2021 as a component of Cost of Revenue in the accompanying Condensed and Consolidated Statement of Operations. Purchase Agreements. The Company enters into standard purchase agreements with vendors in the ordinary course of business, generally with terms that allow cancellation. Legal. The Company may, from time to time, become a party to legal proceedings. Such matters are subject to many uncertainties and to outcomes of which the financial impacts are not predictable with assurance and that may not be known for extended periods of time. A liability is established once management determines a loss is probable and an amount can be reasonably estimated. The Company received a Civil Investigative Demand (CID) from the U.S. Department of Justice (USDOJ) in December 2017 stating that it is investigating the Company to determine whether the Company has violated the False Claims Act, relating to the promotion of certain medical devices related to the treatment of atrial fibrillation for off-label use and submitted or caused to be submitted false claims to certain federal and state health care programs for medically unnecessary healthcare services related to the treatment of atrial fibrillation. The CID covers the period from January 2010 to December 2017 and required the production of documents and answers to written interrogatories. The Company had no knowledge of the investigation prior to receipt of the CID. The Company maintains rigorous policies and procedures to promote compliance with the False Claims Act and other applicable regulatory requirements. The Company provided the USDOJ with documents and answers to the written interrogatories. In March 2021, USDOJ informed the Company that its investigation was based on a lawsuit brought on behalf of the United States and various state and local governments under the qui tam provisions of federal and certain state and local False Claims Acts. Although the USDOJ and all of the state and local governments declined to intervene, the relator continues to pursue the case. While the Company is vigorously contesting the case, it is not possible to predict when this matter may be resolved or what impact, if any, the outcome of this matter might have on our consolidated financial position, results of operations, or cash flows. During the first quarter, the Company received a notice of breach under a license agreement regarding its potential underpayment of royalties. The notice asserts that the Company's calculation of royalties payable under the license agreement throughout the agreement term did not include sales of all products that were subject to royalties. The Company disputes the basis of the claim and any potential underpayment. While a loss related to this claim is possible, the Company does not believe such loss is probable or estimable at this time.

Revenue

Revenue	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Revenue	REVENUEThe Company develops, manufactures and sells devices designed primarily for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and blocking pain by temporarily ablating peripheral nerves. These devices are developed and marketed to a broad base of medical centers globally. The Company recognizes revenue when control of promised goods is transferred to customers in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods. United States revenue by product type is as follows: Three Months Ended Six Months Ended 2022 2021 2022 2021 Open ablation $ 22,070 $ 19,503 $ 41,044 $ 36,942 Minimally invasive ablation 10,154 9,702 18,769 18,087 Pain management 10,210 5,709 18,224 9,607 Total ablation $ 42,434 $ 34,914 $ 78,037 $ 64,636 Appendage management 28,831 25,156 55,500 45,743 Total United States $ 71,265 $ 60,070 $ 133,537 $ 110,379 International revenue by product type is as follows: Three Months Ended Six Months Ended 2022 2021 2022 2021 Open ablation $ 6,213 $ 5,526 $ 12,705 $ 9,960 Minimally invasive ablation 1,271 1,575 2,804 2,849 Pain management 114 11 254 11 Total ablation $ 7,598 $ 7,112 $ 15,763 $ 12,820 Appendage management 5,666 4,194 9,805 7,452 Total International $ 13,264 $ 11,306 $ 25,568 $ 20,272 Revenue attributed to customer geographic locations is as follows: Three Months Ended Six Months Ended 2022 2021 2022 2021 United States $ 71,265 $ 60,070 $ 133,537 $ 110,379 Europe 7,783 7,015 15,020 12,781 Asia 4,933 4,088 9,490 6,961 Other International 548 203 1,058 530 Total International 13,264 11,306 25,568 20,272 Total Revenue $ 84,529 $ 71,376 $ 159,105 $ 130,651

Income Tax Provision

Income Tax Provision	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income Tax Provision	INCOME TAX PROVISION The Company files federal, state and foreign income tax returns in jurisdictions with varying statutes of limitations. The Company uses the asset and liability method to determine its provision for income taxes. The Company’s provision for income taxes in interim periods is computed by applying the discrete method and is based on financial results through the end of the interim period. The Company determined that using the discrete method is more appropriate than using the annual effective tax rate method. The Company is unable to estimate the annual effective tax rate with sufficient precision to use the effective tax rate method, which requires a full-year projection of income. The effective tax rate for the three months ended June 30, 2022 and 2021 was (0.30%) and (0.41%). The effective tax rate for the six months ended June 30, 2022 and 2021 was (0.34%) and (0.29%). The Company’s worldwide effective tax rate differs from the US statutory rate of 21% primarily due to the Company’s valuation allowance. Federal, state and local returns of the Company are routinely subject to review by various taxing authorities. The Company has not accrued any interest and penalties related to unrecognized income tax benefits as a result of offsetting net operating losses. However, if required, the Company will recognize interest and penalties within income tax expense and within the related tax liability.

Equity Compensation Plans

Equity Compensation Plans	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Equity Compensation Plans	EQUITY COMPENSATION PLANS The Company has two share-based incentive plans: the 2014 Stock Incentive Plan (2014 Plan) and the 2019 Employee Stock Purchase Plan (ESPP). Stock Incentive Plan Under the 2014 Plan, the Board of Directors may grant incentive stock options to Company employees and may grant restricted stock awards, restricted stock units, nonstatutory stock options, performance share awards and stock appreciation rights to Company employees, directors and consultants. The Compensation Committee of the Board of Directors, as the administrator of the 2014 Plan, has the authority to determine the terms of any awards, including the number of shares subject to each award, the exercisability of the awards and the form of consideration. As of June 30, 2022, 12,899 shares of common stock had been reserved for issuance under the 2014 Plan, and 1,076 shares were available for future grants. At the Company's 2022 Annual Meeting of Stockholders, stockholders approved an amendment to the 2014 Plan increasing the shares authorized under the 2014 Plan by 1,100. Employee Stock Purchase Plan Under the ESPP, shares of the Company’s common stock may be purchased at a discount (15%) of the lesser of the closing price of the Company’s common stock on the first or last trading days of the offering period. The offering period (currently six months) and the offering price are subject to change. Participants may not purchase more than $25 of the Company’s common stock in a calendar year or more than 3 shares during an offering period. As of June 30, 2022, there were 228 shares available for future issuance under the ESPP. Share-Based Compensation Expense Information The following table summarizes the allocation of share-based compensation expense: Three Months Ended Six Months Ended 2022 2021 2022 2021 Cost of revenue $ 487 $ 598 $ 1,058 $ 1,017 Research and development expenses 1,186 1,083 2,316 2,020 Selling, general and administrative expenses 5,851 5,460 11,199 10,708 Total $ 7,524 $ 7,141 $ 14,573 $ 13,745

Comprehensive Loss and Accumula

Comprehensive Loss and Accumulated Other Comprehensive Loss	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Comprehensive Loss and Accumulated Other Comprehensive Loss	COMPREHENSIVE LOSS AND ACCUMULATED OTHER COMPREHENSIVE LOSS In addition to net losses, comprehensive loss includes foreign currency translation adjustments and unrealized gains (losses) on investments. Accumulated other comprehensive loss consisted of the following, net of tax: Three Months Ended Six Months Ended 2022 2021 2022 2021 Total accumulated other comprehensive (loss) income at beginning of period $ (3,465) $ (18) $ (948) $ 312 Unrealized Gains (Losses) on Investments Balance at beginning of period $ (3,226) $ 23 $ (887) $ 54 Other comprehensive loss before reclassifications (377) (132) (2,716) (163) Amounts reclassified from accumulated other comprehensive loss to other income (expense) (72) — (72) — Balance at end of period $ (3,675) $ (109) $ (3,675) $ (109) Foreign Currency Translation Adjustment Balance at beginning of period $ (239) $ (41) $ (61) $ 258 Other comprehensive income (loss) before reclassifications (527) 36 (787) (262) Amounts reclassified from accumulated other comprehensive loss to other income (expense) 97 27 179 26 Balance at end of period $ (669) $ 22 $ (669) $ 22 Total accumulated other comprehensive loss at end of period $ (4,344) $ (87) $ (4,344) $ (87)

Description of Business and S_2

Description of Business and Summary of Significant Accounting Policies (Policy)	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of the Business	Nature of the Business —The “Company” or “AtriCure” consists of AtriCure, Inc. and its wholly-owned subsidiaries. The Company is a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, and sells its products to medical centers globally through its direct sales force and distributors.
Basis of Presentation	Basis of Presentation —The accompanying interim financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (SEC). All intercompany accounts and transactions have been eliminated in consolidation. The accompanying interim financial statements are unaudited, but in the opinion of the Company’s management, contain all normal, recurring adjustments considered necessary to present fairly the financial position, results of operations and cash flows for the periods presented in conformity with accounting principles generally accepted in the United States of America (GAAP) applicable to interim periods. Certain information and footnote disclosures included in annual financial statements prepared in accordance with GAAP have been omitted or condensed. The Company believes the disclosures herein are adequate to make the information presented not misleading. Results of operations are not necessarily indicative of the results expected for the full year or for any future period.
Use of Estimates	Use of Estimates —The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including intangible assets, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Estimates are based on historical experience, where applicable, and other assumptions believed to be reasonable by management. Actual results could differ from those estimates.
Segments	Segments—The chief operating decision maker for the Company is the Chief Executive Officer. The Chief Executive Officer reviews financial information presented on a consolidated basis, accompanied only by information about revenue by product type and geographic area, for purposes of allocating resources and evaluating financial performance. Accordingly, the Company has determined that it has a single operating segment.
Net Loss Per Share	Net Loss Per Share—Basic and diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common shares outstanding during the period. Since the Company has experienced net losses for all periods presented, net loss per share excludes the effect of 1,548 and 1,807 stock options, restricted shares, restricted stock units and performance award shares as of June 30, 2022 and 2021 because they are anti-dilutive. Therefore, the number of shares calculated for basic net loss per share is also used for the diluted net loss per share calculation.
Fair Value	FAIR VALUE The Financial Accounting Standards Board’s (FASB) Accounting Standards Codification (ASC) 820, “Fair Value Measurements and Disclosures” (ASC 820), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value: • Level 1—Quoted prices in active markets for identical assets or liabilities. • Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
Comprehensive Loss and Accumulated Other Comprehensive Loss	In addition to net losses, comprehensive loss includes foreign currency translation adjustments and unrealized gains (losses) on investments.

Fair Value (Tables)

Fair Value (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following table represents the Company’s fair value hierarchy for its financial assets measured at fair value on a recurring basis as of June 30, 2022: Quoted Prices in Significant Other Significant Other Total Assets: Money market funds $ — $ 48,832 $ — $ 48,832 Commercial paper — 15,940 — 15,940 Government and agency obligations 31,735 — — 31,735 Corporate bonds — 66,789 — 66,789 Asset-backed securities — 13,729 — 13,729 Total assets $ 31,735 $ 145,290 $ — $ 177,025 The following table represents the Company’s fair value hierarchy for its financial assets measured at fair value on a recurring basis as of December 31, 2021: Quoted Prices in Significant Other Significant Other Total Assets: Money market funds $ — $ 38,360 $ — $ 38,360 Commercial paper — 22,978 — 22,978 Government and agency obligations 32,690 — — 32,690 Corporate bonds — 95,845 — 95,845 Asset-backed securities — 28,261 — 28,261 Total assets $ 32,690 $ 185,444 $ — $ 218,134

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2022
Inventory Disclosure [Abstract]
Summary of Inventories	Inventories consist of the following: June 30, December 31, Raw materials $ 14,235 $ 12,653 Work in process 2,742 2,064 Finished goods 24,315 24,247 Total $ 41,292 $ 38,964

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Company's Intangible Assets	The following table provides a summary of the Company’s intangible assets: June 30, 2022 December 31, 2021 Estimated Useful Life Cost Accumulated Cost Accumulated Technology 10 - 15 years $ 55,712 $ 14,663 $ 55,712 $ 12,720
Future Amortization Expense Related to Intangible Assets	Future amortization expense is projected as follows: 2022 (excluding the six months ended June 30, 2022) $ 1,710 2023 2,953 2024 2,953 2025 2,953 2026 2,953 2027 and thereafter 27,527 Total $ 41,049

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Accrued Liabilities	Accrued liabilities consist of the following: June 30, December 31, Accrued compensation and employee-related expenses $ 25,197 $ 30,990 Sales returns and allowances 2,613 2,416 Accrued taxes and value-added taxes payable 1,572 1,452 Other accrued liabilities 1,393 1,234 Total $ 30,775 $ 36,092

Indebtedness (Tables)

Indebtedness (Tables)	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Future Maturities On Debt	Future maturities of long-term debt, excluding the term loan final fee, are projected as follows: 2022 (excluding the six months ended June 30, 2022) $ — 2023 3,333 2024 20,000 2025 20,000 2026 16,667 Total long-term debt $ 60,000

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Summary of Weighted Average Remaining Lease Term and Discount Rate	The weighted average remaining lease term and the discount rate for the reporting periods are as follows: June 30, 2022 December 31, 2021 Operating Leases Weighted average remaining lease term (years) 4.8 3.6 Weighted average discount rate 4.66 % 4.69 % Finance Leases Weighted average remaining lease term (years) 8.1 8.6 Weighted average discount rate 6.92 % 6.91 %
Summary of Components of Lease Expense	The components of lease expense are as follows: Three Months Ended Six Months Ended 2022 2021 2022 2021 Operating lease cost $ 284 $ 203 $ 570 $ 481 Finance lease cost: Amortization of right-of-use assets 338 242 508 484 Interest on lease liabilities 185 200 375 403 Total finance lease cost $ 523 $ 442 $ 883 $ 887
Summary of Supplemental Cash Flow Information Related to Leases	Supplemental cash flow information related to leases was as follows: Six Months Ended Six Months Ended Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 505 $ 494 Operating cash flows for finance leases 375 403 Financing cash flows for finance leases 437 399 Right-of-use assets obtained in exchange for lease obligations: Operating leases — 1,221 Finance leases — —
Summary of Supplemental Balance Sheet Information Related to Leases	Supplemental balance sheet information related to leases was as follows: June 30, 2022 December 31, 2021 Operating Leases Operating lease right-of-use assets $ 4,241 $ 4,761 Current maturities of leases 884 861 Operating lease liabilities 3,591 4,068 Total operating lease liabilities $ 4,475 $ 4,929 Finance Leases Property and equipment, at cost $ 14,607 $ 14,607 Accumulated depreciation (6,624) (6,116) Property and equipment, net $ 7,983 $ 8,491 Current maturities of leases $ 936 $ 895 Finance lease liabilities 9,603 10,082 Total finance lease liabilities $ 10,539 $ 10,977
Schedule of Maturities of Lease Liabilities	aturities of lease liabilities as of June 30, 2022 were as follows: Operating Leases Finance Leases 2022 (excluding the six months ended June 30, 2022) $ 356 $ 817 2023 1,160 1,652 2024 1,164 1,674 2025 920 1,625 2026 592 1,657 2027 and thereafter 868 6,515 Total payments $ 5,060 $ 13,940 Less imputed interest (585) (3,401) Total $ 4,475 $ 10,539

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Revenue By Product Type	United States revenue by product type is as follows: Three Months Ended Six Months Ended 2022 2021 2022 2021 Open ablation $ 22,070 $ 19,503 $ 41,044 $ 36,942 Minimally invasive ablation 10,154 9,702 18,769 18,087 Pain management 10,210 5,709 18,224 9,607 Total ablation $ 42,434 $ 34,914 $ 78,037 $ 64,636 Appendage management 28,831 25,156 55,500 45,743 Total United States $ 71,265 $ 60,070 $ 133,537 $ 110,379 International revenue by product type is as follows: Three Months Ended Six Months Ended 2022 2021 2022 2021 Open ablation $ 6,213 $ 5,526 $ 12,705 $ 9,960 Minimally invasive ablation 1,271 1,575 2,804 2,849 Pain management 114 11 254 11 Total ablation $ 7,598 $ 7,112 $ 15,763 $ 12,820 Appendage management 5,666 4,194 9,805 7,452 Total International $ 13,264 $ 11,306 $ 25,568 $ 20,272
Revenue By Geographic Area	Revenue attributed to customer geographic locations is as follows: Three Months Ended Six Months Ended 2022 2021 2022 2021 United States $ 71,265 $ 60,070 $ 133,537 $ 110,379 Europe 7,783 7,015 15,020 12,781 Asia 4,933 4,088 9,490 6,961 Other International 548 203 1,058 530 Total International 13,264 11,306 25,568 20,272 Total Revenue $ 84,529 $ 71,376 $ 159,105 $ 130,651

Equity Compensation Plans (Tabl

Equity Compensation Plans (Tables)	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation Expense Related To Employee Share-Based Compensation	The following table summarizes the allocation of share-based compensation expense: Three Months Ended Six Months Ended 2022 2021 2022 2021 Cost of revenue $ 487 $ 598 $ 1,058 $ 1,017 Research and development expenses 1,186 1,083 2,316 2,020 Selling, general and administrative expenses 5,851 5,460 11,199 10,708 Total $ 7,524 $ 7,141 $ 14,573 $ 13,745

Comprehensive Loss and Accumu_2

Comprehensive Loss and Accumulated Other Comprehensive Loss (Tables)	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Summary of Accumulated Other Comprehensive Income (Loss)	Accumulated other comprehensive loss consisted of the following, net of tax: Three Months Ended Six Months Ended 2022 2021 2022 2021 Total accumulated other comprehensive (loss) income at beginning of period $ (3,465) $ (18) $ (948) $ 312 Unrealized Gains (Losses) on Investments Balance at beginning of period $ (3,226) $ 23 $ (887) $ 54 Other comprehensive loss before reclassifications (377) (132) (2,716) (163) Amounts reclassified from accumulated other comprehensive loss to other income (expense) (72) — (72) — Balance at end of period $ (3,675) $ (109) $ (3,675) $ (109) Foreign Currency Translation Adjustment Balance at beginning of period $ (239) $ (41) $ (61) $ 258 Other comprehensive income (loss) before reclassifications (527) 36 (787) (262) Amounts reclassified from accumulated other comprehensive loss to other income (expense) 97 27 179 26 Balance at end of period $ (669) $ 22 $ (669) $ 22 Total accumulated other comprehensive loss at end of period $ (4,344) $ (87) $ (4,344) $ (87)

Description of Business and S_3

Description of Business and Summary of Significant Accounting Policies (Narrative) (Details) - USD ($) shares in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Description Of Business And Significant Accounting Policies [Line Items]
Shares not included in the computation of diluted earnings per share	1,548	1,807
Europe
Description Of Business And Significant Accounting Policies [Line Items]
Long-lived assets	$ 1,516		$ 1,399

Fair Value (Narrative) (Details

Fair Value (Narrative) (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Contingent Consideration
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Remaining fair value	$ 0	$ 0

Fair Value (Financial Assets An

Fair Value (Financial Assets And Liabilities Measured At Fair Value On A Recurring Basis) (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Assets:
Assets	$ 177,025	$ 218,134
Money market funds
Assets:
Assets	48,832	38,360
Commercial paper
Assets:
Assets	15,940	22,978
Government and agency obligations
Assets:
Assets	31,735	32,690
Corporate bonds
Assets:
Assets	66,789	95,845
Asset-backed securities
Assets:
Assets	13,729	28,261
Quoted Prices in ‎Active Markets for ‎Identical Assets ‎(Level 1)
Assets:
Assets	31,735	32,690
Quoted Prices in ‎Active Markets for ‎Identical Assets ‎(Level 1) | Money market funds
Assets:
Assets	0	0
Quoted Prices in ‎Active Markets for ‎Identical Assets ‎(Level 1) | Commercial paper
Assets:
Assets	0	0
Quoted Prices in ‎Active Markets for ‎Identical Assets ‎(Level 1) | Government and agency obligations
Assets:
Assets	31,735	32,690
Quoted Prices in ‎Active Markets for ‎Identical Assets ‎(Level 1) | Corporate bonds
Assets:
Assets	0	0
Quoted Prices in ‎Active Markets for ‎Identical Assets ‎(Level 1) | Asset-backed securities
Assets:
Assets	0	0
Significant Other ‎Observable Inputs ‎(Level 2)
Assets:
Assets	145,290	185,444
Significant Other ‎Observable Inputs ‎(Level 2) | Money market funds
Assets:
Assets	48,832	38,360
Significant Other ‎Observable Inputs ‎(Level 2) | Commercial paper
Assets:
Assets	15,940	22,978
Significant Other ‎Observable Inputs ‎(Level 2) | Government and agency obligations
Assets:
Assets	0	0
Significant Other ‎Observable Inputs ‎(Level 2) | Corporate bonds
Assets:
Assets	66,789	95,845
Significant Other ‎Observable Inputs ‎(Level 2) | Asset-backed securities
Assets:
Assets	13,729	28,261
Significant Other ‎Unobservable ‎Inputs (Level 3)
Assets:
Assets	0	0
Significant Other ‎Unobservable ‎Inputs (Level 3) | Money market funds
Assets:
Assets	0	0
Significant Other ‎Unobservable ‎Inputs (Level 3) | Commercial paper
Assets:
Assets	0	0
Significant Other ‎Unobservable ‎Inputs (Level 3) | Government and agency obligations
Assets:
Assets	0	0
Significant Other ‎Unobservable ‎Inputs (Level 3) | Corporate bonds
Assets:
Assets	0	0
Significant Other ‎Unobservable ‎Inputs (Level 3) | Asset-backed securities
Assets:
Assets	$ 0	$ 0

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 14,235	$ 12,653
Work in process	2,742	2,064
Finished goods	24,315	24,247
Total	$ 41,292	$ 38,964

Intangible Assets (Company's In

Intangible Assets (Company's Intangible Assets) (Details) - Technology - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Cost	$ 55,712	$ 55,712
Accumulated Amortization	$ 14,663	$ 12,720
Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life	10 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life	15 years

Intangible Assets (Narrative) (

Intangible Assets (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 971	$ 727	$ 1,943	$ 965

Intangible Assets (Future Amort

Intangible Assets (Future Amortization Expense Related To Intangible Assets With Definite Lives) (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2022 (excluding the six months ended June 30, 2022)	$ 1,710
2023	2,953
2024	2,953
2025	2,953
2026	2,953
2027 and thereafter	27,527
Total	$ 41,049

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued compensation and employee-related expenses	$ 25,197	$ 30,990
Sales returns and allowances	2,613	2,416
Accrued taxes and value-added taxes payable	1,572	1,452
Other accrued liabilities	1,393	1,234
Total	$ 30,775	$ 36,092

Indebtedness (Narrative) (Detai

Indebtedness (Narrative) (Details) - USD ($)	Nov. 01, 2021	Jun. 30, 2022
Line of Credit Facility [Line Items]
Principal payment start	24 months
Amended loan payment deferral period	12 months
Silicon Valley Bank Agreement | Revolving Credit Facility
Line of Credit Facility [Line Items]
Additional borrowings	$ 30,000,000
Annual facility fee	0.20%
Borrowing availability threshold		$ 30,000,000
Line of credit, borrowings		0
Line of credit, revolving line of credit		28,750,000
Term Loan | Silicon Valley Bank Agreement
Line of Credit Facility [Line Items]
Loan amount	$ 60,000,000
Additional borrowings	$ 30,000,000
Maturity period of short term investment	5 years
Annual commitment fee, percentage	3%
Accrued fee amount		240,000
Financing costs		$ 286,000
Term Loan | Silicon Valley Bank Agreement | Prime Rate
Line of Credit Facility [Line Items]
Basis rate	1.25%

Indebtedness (Future Maturities

Indebtedness (Future Maturities On Debt) (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Debt Disclosure [Abstract]
2022 (excluding the six months ended June 30, 2022)	$ 0
2023	3,333
2024	20,000
2025	20,000
2026	16,667
Total long-term debt	$ 60,000

Leases (Narrative) (Details)

Leases (Narrative) (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Lessee, Lease, Description [Line Items]
Letter of credit outstanding	$ 1,250
Minimum
Lessee, Lease, Description [Line Items]
Remaining lease terms	1 year
Maximum
Lessee, Lease, Description [Line Items]
Remaining lease terms	9 years

Leases (Summary Of Weighted Ave

Leases (Summary Of Weighted Average Remaining Lease Term And Discount Rate) (Details)	Jun. 30, 2022	Dec. 31, 2021
Operating Leases
Weighted average remaining lease term (years)	4 years 9 months 18 days	3 years 7 months 6 days
Weighted average discount rate	466%	469%
Finance Leases
Weighted average remaining lease term (years)	8 years 1 month 6 days	8 years 7 months 6 days
Weighted average discount rate	692%	691%

Leases (Summary Of Components O

Leases (Summary Of Components Of Lease Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Leases [Abstract]
Operating lease cost	$ 284	$ 203	$ 570	$ 481
Finance lease cost:
Amortization of right-of-use assets	338	242	508	484
Interest on lease liabilities	185	200	375	403
Total finance lease cost	$ 523	$ 442	$ 883	$ 887

Leases (Summary Of Supplemental

Leases (Summary Of Supplemental Cash Flow Information Related To Leases) (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$ 505	$ 494
Operating cash flows for finance leases	375	403
Financing cash flows for finance leases	437	399
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	0	1,221
Finance leases	$ 0	$ 0

Leases (Summary Of Supplement_2

Leases (Summary Of Supplemental Balance Sheet Information Related To Leases) (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Operating Leases
Operating lease right-of-use assets	$ 4,241	$ 4,761
Current maturities of leases	884	861
Operating lease liabilities	3,591	4,068
Total operating lease liabilities	4,475	4,929
Finance Leases
Property and equipment, at cost	14,607	14,607
Accumulated depreciation	(6,624)	(6,116)
Property and equipment, net	7,983	8,491
Current maturities of leases	936	895
Finance lease liabilities	9,603	10,082
Total finance lease liabilities	$ 10,539	$ 10,977

Leases (Schedule Of Maturities

Leases (Schedule Of Maturities Of Lease Liabilities) (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Operating Leases
2022 (excluding the six months ended June 30, 2022)	$ 356
2023	1,160
2024	1,164
2025	920
2026	592
2027 and thereafter	868
Total payments	5,060
Less imputed interest	(585)
Total	4,475	$ 4,929
Finance Leases
2022 (excluding the six months ended June 30, 2022)	817
2023	1,652
2024	1,674
2025	1,625
2026	1,657
2027 and thereafter	6,515
Total payments	13,940
Less imputed interest	(3,401)
Total	$ 10,539	$ 10,977

Commitments and Contingencies (

Commitments and Contingencies (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Royalty rates			5%
Royalty expense	$ 877	$ 842	$ 1,670	$ 1,564

Revenue (Revenue By Product Typ

Revenue (Revenue By Product Type) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue from External Customer [Line Items]
Revenue	$ 84,529	$ 71,376	$ 159,105	$ 130,651
United States
Revenue from External Customer [Line Items]
Revenue	71,265	60,070	133,537	110,379
United States | Total ablation
Revenue from External Customer [Line Items]
Revenue	42,434	34,914	78,037	64,636
United States | Open ablation
Revenue from External Customer [Line Items]
Revenue	22,070	19,503	41,044	36,942
United States | Minimally invasive ablation
Revenue from External Customer [Line Items]
Revenue	10,154	9,702	18,769	18,087
United States | Pain management
Revenue from External Customer [Line Items]
Revenue	10,210	5,709	18,224	9,607
United States | Appendage management
Revenue from External Customer [Line Items]
Revenue	28,831	25,156	55,500	45,743
Total International
Revenue from External Customer [Line Items]
Revenue	13,264	11,306	25,568	20,272
Total International | Total ablation
Revenue from External Customer [Line Items]
Revenue	7,598	7,112	15,763	12,820
Total International | Open ablation
Revenue from External Customer [Line Items]
Revenue	6,213	5,526	12,705	9,960
Total International | Minimally invasive ablation
Revenue from External Customer [Line Items]
Revenue	1,271	1,575	2,804	2,849
Total International | Pain management
Revenue from External Customer [Line Items]
Revenue	114	11	254	11
Total International | Appendage management
Revenue from External Customer [Line Items]
Revenue	$ 5,666	$ 4,194	$ 9,805	$ 7,452

Revenue (Revenue By Geographic

Revenue (Revenue By Geographic Area) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 84,529	$ 71,376	$ 159,105	$ 130,651
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	71,265	60,070	133,537	110,379
Europe
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	7,783	7,015	15,020	12,781
Asia
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	4,933	4,088	9,490	6,961
Other International
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	548	203	1,058	530
Total International
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 13,264	$ 11,306	$ 25,568	$ 20,272

Income Tax Provision (Narrative

Income Tax Provision (Narrative) (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Effective tax rate	(0.30%)	(0.41%)	(0.34%)	(0.29%)

Equity Compensation Plans (Narr

Equity Compensation Plans (Narrative) (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($) item shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of share-based incentive plans (in shares) | item	2
Offering period	6 months
Participants purchase limit shares (in shares)	3,000
2014 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance (in shares)	12,899,000
Shares available for future grants (in shares)	1,076,000
Additional shares authorized (in shares)	1,100,000
2008 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance (in shares)	228,000
Company's common stock may be purchased at a discount (percent)	15%
Participants purchase limit value | $	$ 25

Equity Compensation Plans (Shar

Equity Compensation Plans (Share-Based Compensation Expense Related To Employee Share-Based Compensation) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total	$ 7,524	$ 7,141	$ 14,573	$ 13,745
Cost of revenue
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total	487	598	1,058	1,017
Research and development expenses
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total	1,186	1,083	2,316	2,020
Selling, general and administrative expenses
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total	$ 5,851	$ 5,460	$ 11,199	$ 10,708

Comprehensive Loss and Accumu_3

Comprehensive Loss and Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive (loss) income, beginning of period	$ (3,465)	$ (18)	$ (948)	$ 312
Accumulated other comprehensive (loss) income, end of period	(4,344)	(87)	(4,344)	(87)
Unrealized Gains (Losses) on Investments
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive (loss) income, beginning of period	(3,226)	23	(887)	54
Other comprehensive income (loss) before reclassifications	(377)	(132)	(2,716)	(163)
Amounts reclassified from accumulated other comprehensive loss to other income (expense)	(72)	0	(72)	0
Accumulated other comprehensive (loss) income, end of period	(3,675)	(109)	(3,675)	(109)
Foreign Currency Translation Adjustment
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive (loss) income, beginning of period	(239)	(41)	(61)	258
Other comprehensive income (loss) before reclassifications	(527)	36	(787)	(262)
Amounts reclassified from accumulated other comprehensive loss to other income (expense)	97	27	179	26
Accumulated other comprehensive (loss) income, end of period	$ (669)	$ 22	$ (669)	$ 22